Back

The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects

25 April 2024 (09:00 - 12:30)
Organised by: Logo
Congress Presentation Part of: Advances in risk stratification and lipid management Drug therapy Open Access ESC Preventive Cardiology 2024 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Mrs Trine Lauritzen

Drammen Hospital, Drammen (Norway)

6 More presentations in this session

Presentation thumbnail
Unlinking sudden death from coronary artery disease - a systematic scoping review of the association of low-density lipoprotein cholesterol and sudden death
Ms R. Beyer (Berlin, DE)
Abstract Slides
Presentation thumbnail
The association between the remnant cholesterol and non-HDL-C with subclinical carotid atherosclerosis in patients with metabolic syndrome
Professor I. Tasic (Niska Banja, RS)
Abstract Slides
Presentation thumbnail
A polyphenol-rich active substance (TOTUM-070) lowers LDL-cholesterol in subjects with moderate hypercholesterolemia. The OLALIP study
Doctor Y. Otero (Perigny, FR)
Abstract Slides
Presentation thumbnail
Lipoprotein(a) and referrals to a specialist lipid clinic
Doctor C. Kennedy (Dublin, IE)
Abstract Slides
Presentation thumbnail
Lp(a) and vascular inflammation: data from perivascular fat attenuation index measurements
Doctor S. Simantiris (Athens, GR)
Abstract Slides

Access the full session

Session thumbnail
Advances in risk stratification and lipid management

The Event

Event poster

ESC Preventive Cardiology 2024

25 April - 27 April 2024
You may be interested in
thumbnail
Congress Presentation
Lipid control in cardiovascular patients
thumbnail
Congress Presentation
Fix the plaque, fight the lipids: why low-density lipoproteins still matter after percutaneous coronary intervention
thumbnail
Congress Presentation
What’s new in LDL lowering?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources